CMC Biologics announces development and manufacturing agreement with Harpoon Therapeutics.
CMC ICOS Biologics, Inc., a clinical and commercial manufacturer of therapeutic proteins, and Harpoon Therapeutics, an immuno-oncology company using its proprietary TriTAC technology platform to discover and develop novel biologics for the treatment of cancer, have entered into an agreement for the development and manufacturing of HPN424, HPN536, and HPN217, representing three TriTAC molecules for the treatment of various human cancers.
Harpoon Therapeutics’ TriTAC molecules are half-life extended and designed to simultaneously bind to cancer cells and T-cells, triggering those T-cells to attack the targeted cancer cells. These molecules contain three binding domains: one domain binds a specific tumor target, the second domain binds to human serum albumin, and the third domain binds to T-cells.
Harpoon’s first clinical candidate, HPN424, a prostate-specific membrane antigen (PSMA)-targeting TriTAC, is in development for the treatment of metastatic prostate cancer and expected to enter Phase 1 clinical trials in 2018.
(Source: CMC ICOS Biologics, Inc.)
